SCHEMBL3370975

SCHEMBL3370975

COCCOc1cccc2[nH]c(C(Cl)(Cl)Cl)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.48
DRD4 P21917 3/20 0.48
DRD3 P35462 3/20 0.48
GNRHR P30968 6/20 0.46
HTR1A P08908 3/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
CBFB Q13951 2/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MIF P14174 1/20 0.38
MAOB P27338 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368854 0.86 NCF1 (0.50) DRD2DRD4DRD3GNRHRHTR1A
SCHEMBL3372705 0.83 DRD2 (0.44) DRD2DRD4DRD3GNRHRHTR1A
SCHEMBL30402813 0.82 ALDH1A1 (0.51) DRD2DRD4DRD3CBFBALDH1A1
SCHEMBL213419 0.80 DRD2 (0.44) DRD2DRD4DRD3CBFBALDH1A1
SCHEMBL3368709 0.76 MAOB (0.45) DRD2DRD4DRD3CBFBALDH1A1
SCHEMBL30341889 0.75 DRD4 (0.57) DRD2DRD4DRD3GNRHRHTR1A
Benzimidazole SCHEMBL6017034 0.75 DRD2 (0.40) DRD2DRD4DRD3GNRHRHTR1A
SCHEMBL2842465 0.72 DRD2 (0.43) DRD2DRD4DRD3HTR1AHTR1D
SCHEMBL29338407 0.71 MIF (0.41) DRD2DRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL4352212 0.71 MGAM (0.55) CBFBALDH1A1ADORA2AGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP disclosed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US disclosed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP disclosed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US disclosed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 DRD2 3083/4885DRD4 3857/4885DRD3 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.